EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Real‐life effectiveness 1 year after switching to avalglucosidase alfa in late‐onset Pompe disease patients worsening on alglucosidase alfa therapy: A French cohort study

Céline Tard iD, Françoise Bouhour, Maud Michaud, Stephane Beltran iD, Maxime Fournier, Florence Demurger, Emmeline Lagrange iD, Sylvain Nollet, Sabrina Sacconi, Jean-Baptiste Noury, Armelle Magot iD, Pascal Cintas und 11 weitere

European Journal of Neurology · 2024-07 · 31 (7)

DOI: 10.1111/ene.16292 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift European Journal of Neurology, online erschienen am 08.04.2024. Verfasst von Céline Tard und 22 weiteren Autor:innen. Beteiligte Einrichtung: Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience and Cognition, University of Lille, Lille, France. Hauptthemen laut MEDLINE: Glycogen Storage Disease Type II, alpha-Glucosidases, Enzyme Replacement Therapy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Amicus Therapeutics, Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Late‐onset Pompe disease (LOPD) is characterized by a progressive myopathy resulting from a deficiency of acid α‐glucosidase enzyme activity. Enzyme replacement therapy has been shown to be effective, but long‐term treatment results vary. Avalglucosidase alfa demonstrated non‐inferiority to alglucosidase alfa in a phase 3 study, allowing in France compassionate access for advanced LOPD patients unresponsive to alglucosidase alfa.

Methods

Data from the French Pompe registry were analyzed for patients who benefited from a switch to avalglucosidase alfa with at least 1 year of follow‐up. Respiratory (forced vital capacity [FVC]) and motor functions (Six‐Minute Walk Test [6MWT]) were assessed before and 1 year after switching. Individual changes in FVC and 6MWT were expressed as slopes and statistical analyses were performed to compare values.

Results

Twenty‐nine patients were included (mean age 56 years, 11 years of prior treatment). The FVC and 6MWT values remained stable. The individual analyses showed a stabilization of motor worsening: –1 m/year on the 6MWT after the switch versus –63 m/year the year before the switch (i.e., a worsening of 33%/year before vs. an improvement of 3%/year later). Respiratory data were not statistically different.

Discussion

At the group level, gait parameters improved slightly with a stabilization of previous worsening, but respiratory parameters showed limited changes. At the individual level, results were discordant, with some patients with a good motor or respiratory response and some with further worsening.

Conclusion

Switching to avalglucosidase alfa demonstrated varied responses in advanced LOPD patients with failing alglucosidase alfa therapy, with a general improvement in motor stabilization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glycogen Storage Disease Type IIalpha-GlucosidasesEnzyme Replacement TherapyHumansMaleMiddle AgedFemaleFranceAgedAdultCohort StudiesTreatment OutcomeRegistriesDisease ProgressionWalk TestDrug Substitution

Stichwörter der Autor:innen

enzymotherapyglycogenosisswitchtreatment managementunmet needs

Substanzen

alpha-GlucosidasesGAA protein, human

Autor:innen und Institutionen

  • Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience and Cognition, University of Lille, Lille, France.
  • Centre de Référence des Maladies NeuroMusculaires Nord - Est - Ile-de-France, Filnemus, Garches, France.
  • Centre de Référence des Maladies NeuroMusculaires PACA Réunion Rhône Alpes, Filnemus, Marseille, France.
  • Service ENMG/Pathologies Neuromusculaires, Hospices Civils de Lyon, Lyon, France.
  • Service de Neurologie, CHU de Nancy, Nancy, France.
  • Service de Neurologie, CHRU Bretonneau, Tours, France.

ORCID-Profile: Céline Tard, Stephane Beltran, Emmeline Lagrange, Armelle Magot

Förderung

  • Amicus Therapeutics
  • Sanofi

Zitieren

APA

Tard, C., Bouhour, F., Michaud, M., Beltran, S., Fournier, M., Demurger, F., Lagrange, E., Nollet, S., Sacconi, S., Noury, J. B., Magot, A., Cintas, P., Renard, D., Deibener-Kaminsky, J., Lefeuvre, C., Davion, J. B., Salort-Campana, E., Arrassi, A., Taouagh, N., …, & Laforêt, P. (2024). Real‐life effectiveness 1 year after switching to avalglucosidase alfa in late‐onset Pompe disease patients worsening on alglucosidase alfa therapy: A French cohort study. European Journal of Neurology, 31(7). https://doi.org/10.1111/ene.16292

Vancouver

Tard C, Bouhour F, Michaud M, Beltran S, Fournier M, Demurger F, et al. Real‐life effectiveness 1 year after switching to avalglucosidase alfa in late‐onset Pompe disease patients worsening on alglucosidase alfa therapy: A French cohort study. European Journal of Neurology. 2024;31(7). doi:10.1111/ene.16292

BibTeX
@article{Tard2024,
  author = {Tard, Céline and Bouhour, Françoise and Michaud, Maud and Beltran, Stephane and Fournier, Maxime and Demurger, Florence and Lagrange, Emmeline and Nollet, Sylvain and Sacconi, Sabrina and Noury, Jean-Baptiste and Magot, Armelle and Cintas, Pascal and Renard, Dimitri and Deibener-Kaminsky, Joëlle and Lefeuvre, Claire and Davion, Jean-Baptiste and Salort-Campana, Emmanuelle and Arrassi, Azzeddine and Taouagh, Nadjib and Spinazzi, Marco and Pompe Study Group, Pompe Study Group and Attarian, Shahram and Laforêt, Pascal},
  title = {Real‐life effectiveness 1 year after switching to avalglucosidase alfa in late‐onset Pompe disease patients worsening on alglucosidase alfa therapy: A French cohort study},
  journal = {European Journal of Neurology},
  year = {2024},
  volume = {31},
  number = {7},
  doi = {10.1111/ene.16292}
}
Kostenlos starten →